Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29156418 | 1.00 | KMT2A (0.44) | KMT2AMMP1MMP13CHRNB2CHRNA4 | |
| SCHEMBL18215900 | 1.00 | KMT2A (0.44) | KMT2AMMP1MMP13CHRNB2CHRNA4 | |
| SCHEMBL23677559 | 1.00 | KMT2A (0.44) | KMT2AMMP1MMP13CHRNB2CHRNA4 | |
| SCHEMBL16229720 | 0.81 | KMT2A (0.44) | KMT2AMMP1MMP13CHRNB2CHRNA4 | |
| SCHEMBL10410305 | 0.81 | KMT2A (0.44) | KMT2AMMP1MMP13CHRNB2CHRNA4 | |
| SCHEMBL16229721 | 0.81 | KMT2A (0.44) | KMT2AMMP1MMP13CHRNB2CHRNA4 | |
| SCHEMBL30233062 | 0.81 | KMT2A (0.44) | KMT2AMMP1MMP13CHRNB2CHRNA4 | |
| SCHEMBL18593156 | 0.80 | ALDH1A1 (0.40) | KMT2A | |
| SCHEMBL18204760 | 0.79 | KMT2A (0.42) | KMT2AMMP1MMP13CHRNB2CHRNA4 | |
| SCHEMBL20077557 | 0.79 | KMT2A (0.42) | KMT2AMMP1MMP13CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025106362-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2025-05-22 | — | — | WO | disclosed |
| CN-110278711-B | Tricyclosulfones as rory modulators | 百时美施贵宝公司 | 2023-12-15 | — | — | CN | disclosed |
| EP-3541786-B1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-05 | — | — | EP | disclosed |
| US-10435369-B2 | Tricyclic sulfones as ROR gamma modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-10-08 | — | — | US | disclosed |
| US-20180127368-A1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435369-B2 | Tricyclic sulfones as ROR gamma modulators | RORC, RORB, RORA | KMT2A 2753/4885MMP1 4162/4885MMP13 3770/4885 |
| US-20180127368-A1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | RORC, RORB, RORA | KMT2A 2753/4885MMP1 4162/4885MMP13 3770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.